Veterinary CRO And CDMO Market size surpassed USD 5.51 Billion in 2022 and is poised to reach USD 12.56 Billion, growing at over 10.28% CAGR between 2023 and 2030.
Growth Drivers & Opportunities:
1. Emerging Veterinary Drug Development: The increasing demand for innovative and effective veterinary drugs has propelled the growth of the Veterinary CRO and CDMO market. As the number of diseases and conditions affecting animals continues to rise, there is a need for advanced research and development in this field.
2. Outsourcing of Research Activities: Many pharmaceutical and biotechnology companies are turning to CRO and CDMO services to outsource various research activities. This trend has driven the growth of the market as outsourcing provides cost-effective solutions and specialized expertise required for veterinary drug development.
Industry Restraints & Challenges:
1. Stringent Regulatory Approval Process: The approvals and regulations surrounding the development and manufacturing of veterinary drugs can be stringent. These regulations pose a challenge to CROs and CDMOs as they must ensure compliance with all regulatory requirements, which can sometimes lead to delays in the drug development process.
Report Coverage | Details |
---|---|
Segments Covered | Animal Type, Service Type, Application, Region |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Labcorp Drug Development, Charles River Laboratories., Clinvet, KLIFOVET GmbH (Argenta Group), OCR Oncovet Clinical Research, Knoell Triveritas, Veterinary Research Management, VETSPIN, Inotiv., IDEXX Laboratories, Zoetis Nexvet, Vetio |
2. High Costs of Research and Development: The veterinary drug development process can be expensive due to the need for extensive research, clinical trials, and manufacturing. This high cost can act as a restraint for smaller players in the market.
In conclusion, the Veterinary CRO and CDMO market is experiencing significant growth due to the increasing demand for innovative veterinary drugs. However, challenges such as stringent regulations and high costs of research and development continue to impact the market. Despite these challenges, the market outlook remains positive, with ample opportunities for growth and expansion in the coming years.
In terms of the regional forecast, the veterinary CRO and CDMO market can be segmented into North America, Asia Pacific, and Europe. Each region exhibits unique growth opportunities and challenges for the market players.
North America:
The North American market for veterinary CRO and CDMO is expected to witness significant growth during the forecast period. Factors contributing to this growth include the rising pet ownership rates, increasing expenditure on pet healthcare, and the presence of well-established veterinary pharmaceutical companies. Additionally, technologically advanced veterinary healthcare infrastructure and the presence of key market players further propel the growth in this region.
Asia Pacific:
The Asia Pacific region is also poised to experience substantial growth in the veterinary CRO and CDMO market. The rising disposable income and changing lifestyle patterns have led to increased pet ownership and a greater focus on pet healthcare. Moreover, the growing awareness regarding animal welfare and the increasing demand for animal-derived products, such as meat and milk, drive the need for veterinary CRO and CDMO services in this region. Growing economies like India and China offer immense growth potential in the market.
Europe:
Europe is another significant region in the veterinary CRO and CDMO market. The region witnesses high expenditure on animal healthcare and boasts a well-established veterinary healthcare infrastructure. Factors such as stringent regulatory frameworks, increasing pet adoption rates, and the rising prevalence of zoonotic diseases drive the demand for veterinary CRO and CDMO services in Europe. Additionally, the presence of key market players and continuous innovation in veterinary drugs and therapeutics further augment the market growth.